896 related articles for article (PubMed ID: 31095767)
21. Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change?
Calderón MA; Bousquet J; Canonica GW; Cardell LO; Fernandez de Rojas DH; Kleine-Tebbe J; Demoly P
J Allergy Clin Immunol; 2017 Jul; 140(1):41-52. PubMed ID: 28526624
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma.
Farraia M; Paciência I; Castro Mendes F; Cavaleiro Rufo J; H Shamji M; Agache I; Moreira A
Allergy; 2022 Sep; 77(9):2688-2698. PubMed ID: 35451128
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
24. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.
Devillier P; Fadel R; de Beaumont O
Allergy; 2016 Feb; 71(2):249-57. PubMed ID: 26465232
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps?
Biagtan M; Viswanathan R; Bush RK
Curr Allergy Asthma Rep; 2014 Dec; 14(12):482. PubMed ID: 25354663
[TBL] [Abstract][Full Text] [Related]
26. Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.
Larenas-Linnemann D; Rodríguez-Pérez N; Luna-Pech JA; Rodríguez-González M; Blandón-Vijil MV; Del-Río-Navarro BE; Costa-Domínguez MDC; Navarrete-Rodríguez EM; Macouzet-Sánchez C; Ortega-Martell JA; Pozo-Beltrán CF; Estrada-Cardona A; Arias-Cruz A; Rodríguez Galván KG; Brito-Díaz H; Canseco-Raymundo MDR; Castelán-Chávez EE; Escalante-Domínguez AJ; Gálvez-Romero JL; Gómez-Vera J; González-Díaz SN; Guerrero-Núñez MGB; Hernández-Colín DD; Macías-Weinmann A; Mendoza-Hernández DA; Meneses-Sánchez NA; Mogica-Martínez MD; Moncayo-Coello CV; Montiel-Herrera JM; O'Farril-Romanillos PM; Onuma-Takane E; Ortega-Cisneros M; Rangel-Garza L; Stone-Aguilar H; Torres-Lozano C; Venegas-Montoya E; Wakida-Kusunoki G; Partida-Gaytán A; López-García AI; Macías-Robles AP; Ambriz-Moreno MJ; Azamar-Jácome AA; Beltrán-De Paz CY; Caballero-López C; Fernández de Córdova-Aguirre JC; Fernández-Soto JR; Lozano-Sáenz JS; Oyoqui-Flores JJ; Osorio-Escamilla RE; Ramírez-Jiménez F; Rivero-Yeverino D; Martínez Infante E; Medina-Ávalos MA
World Allergy Organ J; 2020 Aug; 13(8):100444. PubMed ID: 32884611
[TBL] [Abstract][Full Text] [Related]
27. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma.
Blumberga G; Groes L; Dahl R
Allergy; 2011 Feb; 66(2):178-85. PubMed ID: 20883456
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
29. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
30. Serum-specific IgE and allergen immunotherapy in allergic children.
Tosca M; Silvestri M; Accogli A; Rossi GA; Ciprandi G
Immunotherapy; 2014; 6(1):29-33. PubMed ID: 24341881
[TBL] [Abstract][Full Text] [Related]
31. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
32. Advances in allergen immunotherapy for asthma.
Agache I; Laculiceanu A; Cojanu C; Spanu D; Rogozea L
Curr Opin Allergy Clin Immunol; 2020 Dec; 20(6):602-608. PubMed ID: 32769712
[TBL] [Abstract][Full Text] [Related]
33. The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation.
Kito H; Du W; Nakazawa H; Lund K; Ohashi-Doi K
Biol Pharm Bull; 2019; 42(6):1030-1033. PubMed ID: 31155578
[TBL] [Abstract][Full Text] [Related]
34. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.
Yang Y; Ma D; Huang N; Li W; Jiang Q; Wang Y; Wang X; Yang L; Zhu R
Ital J Pediatr; 2021 Apr; 47(1):101. PubMed ID: 33892756
[TBL] [Abstract][Full Text] [Related]
35. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
Meteran H; Backer V
Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
[No Abstract] [Full Text] [Related]
36. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.
Klimek L; Mosbech H; Zieglmayer P; Rehm D; Stage BS; Demoly P
Expert Rev Clin Immunol; 2016; 12(4):369-77. PubMed ID: 26788764
[TBL] [Abstract][Full Text] [Related]
37. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
[TBL] [Abstract][Full Text] [Related]
38. Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma.
Creticos PS; Gunaydin FE; Nolte H; Damask C; Durham SR
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1415-1427. PubMed ID: 38685477
[TBL] [Abstract][Full Text] [Related]
39. Principles of Allergen Immunotherapy and Its Clinical Application in China: Contrasts and Comparisons with the USA.
Guan K; Liu B; Wang M; Li Z; Chang C; Cui L; Wang RQ; Wen LP; Leung PSC; Wei JF; Sun JL
Clin Rev Allergy Immunol; 2019 Aug; 57(1):128-143. PubMed ID: 31243705
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
